PPP2R2A and prostate adenocarcinoma: This is consistent with the DFS calculated in an independent cohort with hemizygous loss of PPP2R2A (the MSKCC prostate adenocarcinoma data set, 194 tumors, p-value of 0.0053, Suppl.